Ely Benaim - Mar 3, 2022 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Medical Officer
Signature
By: /s/ Steven Robbins, Attorney in Fact for Ely Benaim
Stock symbol
NVCR
Transactions as of
Mar 3, 2022
Transactions value $
$2,724,949
Form type
4
Date filed
3/7/2022, 05:18 PM
Previous filing
Jan 12, 2022
Next filing
May 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $0 +17.4K +61.6% $0.00 45.6K Mar 3, 2022 Direct F1
transaction NVCR Ordinary Shares Sale -$59.8K -803 -1.76% $74.50 44.8K Mar 3, 2022 Direct F2
transaction NVCR Ordinary Shares Sale -$106K -1.51K -3.37% $70.41 43.3K Mar 4, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVCR Options to Buy Ordinary Shares Award $2.45M +30.4K $80.59 30.4K Mar 3, 2022 Ordinary Shares 30.4K $80.59 Direct F3
transaction NVCR Options to Buy Ordinary Shares Award $439K +5.45K $80.59 5.45K Mar 3, 2022 Ordinary Shares 5.45K $80.59 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates.
F2 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F3 Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates.
F4 Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates.